FDA Exclusivities, PTA, PTE, and ODP Shape Pharmaceutical Lifecycle Value
Summary
Sterne Kessler Directors Deborah Sterling, John Covert, and Dennies Varughese presented a webinar summarizing five practical insights for pharmaceutical lifecycle strategy. The article covers how FDA regulatory exclusivities, patent term adjustment (PTA), patent term extension (PTE), and obviousness-type double patenting (ODP) interact to affect competitive entry timing. Key points include regulatory exclusivity operating as a standalone barrier, PTA introducing double patenting risk when disproportionate across related patents, and the importance of holistic planning across regulatory, prosecution, and enforcement teams to preserve product value through loss of exclusivity.
“Pharmaceutical lifecycle value is often at its highest towards the end of the patent term.”
About this source
JD Supra is the legal industry's open library where US law firms publish client alerts and regulatory analysis. The Healthcare section aggregates everything from partners covering CMS reimbursement, HIPAA enforcement, FDA compliance, healthcare M&A, fraud and abuse, payer-provider disputes, telehealth, and the fast-moving state regulation of healthcare AI. Around 250 alerts a month. Watch this if you run a hospital legal department, advise digital health startups, manage payer compliance, or track how state Medicaid agencies and HHS-OIG actually enforce the rules they publish. The signal-to-noise ratio is genuinely good because firms only publish when they have something concrete to say to their clients. GovPing pulls each alert with the firm name, author, and topic.
What changed
This article summarizes a law firm webinar on pharmaceutical lifecycle strategy, outlining five insights: FDA exclusivities can function independently from patents; PTA may increase double patenting exposure; PTE selection requires balancing term length against claim scope and enforceability; ODP analysis has become more fact-specific under recent decisions; and coordinated planning across regulatory, patent, and litigation functions preserves product value. The article does not create new legal obligations but provides strategic commentary for pharmaceutical companies navigating exclusivity mechanisms. Compliance teams should treat this as informational context for understanding FDA regulatory exclusivity interactions with patent protections rather than as binding guidance.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
April 23, 2026
Key Takeaways: How Regulatory Exclusivity, PTA, PTE, and Double Patenting Shape Pharmaceutical Lifecycle Value
John Covert, Deborah Sterling, Ph.D., Dennies Varughese Pharm.D. Sterne, Kessler, Goldstein & Fox P.L.L.C. + Follow Contact LinkedIn Facebook X ;) Embed
Pharmaceutical lifecycle value is often at its highest towards the end of the patent term. With longer development timelines and potential patent challenges, life sciences companies must understand how FDA regulatory exclusivities, patent term adjustment (PTA), patent term extension (PTE), and obviousness-type double patenting (ODP) interact. Relatively small timing differences can significantly affect competitive entry and business outcomes.
During our recent webinar, Counting the Days—How Regulatory Exclusivity, PTE, PTA, and ODP Coalesce to Influence Lifecycle, Sterne Kessler Directors Deborah Sterling, Ph.D., John Covert, and Dennies Varughese highlighted several practical insights for companies developing a lifecycle strategy for their products.
- Regulatory Exclusivity Can Operate as a Standalone Barrier: FDA exclusivities may delay competition even if patents expire earlier or are successfully challenged, providing meaningful independent protection.
- PTA Extends Term but May Introduce Risk: While PTA can add valuable time to a patent’s life, disproportionate PTA across related patents can increase exposure to double patenting challenges.
- PTE Selection Is a Strategic Choice: Choosing which patent to extend requires balancing term length against claim scope, enforceability, and vulnerability to invalidity or ODP attacks.
- ODP Analysis Is Increasingly Fact-Specific: Recent decisions emphasize filing sequence and family structure, underscoring the importance of evaluating ODP risk across entire portfolios.
- Holistic Planning Preserves Value: Aligning regulatory exclusivities, patent strategy, and litigation planning enhances predictability and helps preserve value through loss of exclusivity. Maximizing exclusivity requires coordinated planning across regulatory, prosecution, and enforcement teams. By treating regulatory exclusivities, PTA, PTE, and ODP as interconnected tools, companies can better protect innovation, anticipate loss-of-exclusivity timing, and support sound commercial decision-making. Ongoing monitoring and early strategic alignment remain essential as this area of law continues to evolve. Watch the on demand webinar for further analysis.
;) ;) Report
Latest Posts
- Key Takeaways: How Regulatory Exclusivity, PTA, PTE, and Double Patenting Shape Pharmaceutical Lifecycle Value
- TTAB Reminds Businesses That Trade Name Use Is Not Trademark Use, in Maple Leaf Cheesemakers Decision
- IP Hot Topic: National Phase Patent Choices – Proceed, Postpone, or Part Ways With the PIER Pilot Program
- Key Provisions of the Remedy Act and Their Impact on Hatch‑Waxman Litigation
- AI Is Not Your Lawyer: Discovery Risks for Legal and IP Strategy See more »
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.
©
Sterne, Kessler, Goldstein & Fox P.L.L.C.
Written by:
Sterne, Kessler, Goldstein & Fox P.L.L.C. Contact + Follow John Covert + Follow Deborah Sterling, Ph.D. + Follow Dennies Varughese Pharm.D. + Follow more less
PUBLISH YOUR CONTENT ON JD SUPRA
- ✔ Increased readership
- ✔ Actionable analytics
- ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra
Published In:
Food and Drug Administration (FDA) + Follow Hatch-Waxman + Follow Life Sciences + Follow Obviousness-Type Double Patenting (ODP) + Follow Patent Litigation + Follow Patent Prosecution + Follow Patent Term Adjustment + Follow Patent Term Extensions + Follow Patents + Follow Pharmaceutical Industry + Follow Pharmaceutical Patents + Follow Regulatory Requirements + Follow Health + Follow Intellectual Property + Follow Science, Computers & Technology + Follow more less
Sterne, Kessler, Goldstein & Fox P.L.L.C. on:
"My best business intelligence, in one easy email…"
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide
Mentioned entities
Related changes
Get daily alerts for JD Supra Healthcare
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from Sterne Kessler.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when JD Supra Healthcare publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.